# Center fro Male Reproductive Epigenomics

> **NIH NIH P50** · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · 2023 · $159,417

## Abstract

Project Summary
While traditional genetic studies to investigate DNA or RNA nucleotide information, epigenetic analyses aim to
characterize chemical modifications within both DNA/RNA sequences and histone proteins. Epigenetic changes
are preserved during cell division and potentially modify the expression of certain genes instead of altering the
genetic code of nucleotide sequences, which is not only due to regular and natural occurrence but also influenced
by several factors including age, the environment/lifestyle, and disease status. More importantly, some
epigenetic modifications can potentially be transmitted to offspring by transgenerational epigenetic inheritance.
Our more recent study suggests that this intergenerational transmission of paternally acquired metabolic
disorders is mediated by a nucleic acid modification enzyme called DNA (cytosine-5-)-methyltransferase 2
(Dnmt2). Inspired by these findings, this P50 will focus on the relationship between epigenetic profiles and
metabolic disorders in both animal models and human subjects. To study the epigenetic regulation, it is critical
to know not only what kinds of modifications are present but also their genomic loci. Therefore, high-throughput
sequencing will be applied to profile epigenetic alterations in both animal and human samples. This Epigenomics
Core (Core D) will provide essential, cutting edge, bioinformatical expertise to facilitate the translational impact
of this highly integrated P50. Firstly, Core D will coordinate outsource library sequencing for individual projects
(Specific Aim #1). Secondly, Core D will provide centralized computational service to store, process, and
analyze the sequencing data, using our in-house well-characterized pipelines (Specific Aims #2). Finally, Core
D will be responsible for hosting an in-house web-based server to share the omics data (Specific Aim #3), which
provides both the internal and external researchers an easy access to the data generated from individual projects.

## Key facts

- **NIH application ID:** 10615596
- **Project number:** 5P50HD098593-04
- **Recipient organization:** LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
- **Principal Investigator:** Tong Zhou
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $159,417
- **Award type:** 5
- **Project period:** 2019-09-13 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10615596

## Citation

> US National Institutes of Health, RePORTER application 10615596, Center fro Male Reproductive Epigenomics (5P50HD098593-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10615596. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*